Please login to the form below

Not currently logged in

Novartis' patupilone fails phase III trial

Novartis has announced that its investigative compound, patupilone, has failed a phase III trial of patients with advanced ovarian cancer

Novartis has announced that its investigative compound, patupilone (EPO906), has failed a phase III trial of patients with advanced ovarian cancer, refractory or resistant to platinum-based therapy.

The compound was tested in a phase III study carried out in around 168 sites across 22 countries. The randomised study, which involved 829 patients with epithelial ovarian, primary fallopian or primary peritoneal cancer, compared patupilone with Doxil/Caelyx (pegylated liposomal doxorubicin).

The primary endpoint of the trial was overall survival. Secondary endpoints included progression-free survival, safety and overall response rate. Patupilone did not show a significant overall survival advantage. Based on this, Novartis does not plan to proceed with regulatory filings based on these data.

27th May 2010


Featured jobs

Subscribe to our email news alerts


Add my company

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...